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The 34 allele of apolipoprotein E (APOE) is the major genetic risk factor for Alzheimer’s disease (AD). Although
there have been numerous studies attempting to elucidate the underlying mechanism for this increased risk,
how apoE4 influences AD onset and progression has yet to be proven. However, prevailing evidence
suggests that the differential effects of apoE isoforms on Ab aggregation and clearance play the major
role in AD pathogenesis. Other potential mechanisms, such as the differential modulation of neurotoxicity
and tau phosphorylation by apoE isoforms as well as its role in synaptic plasticity and neuroinflammation,
have not been ruled out. Inconsistent results among studies have made it difficult to define whether the
APOE 34 allele represents a gain of toxic function, a loss of neuroprotective function, or both. Therapeutic
strategies based on apoE propose to reduce the toxic effects of apoE4 or to restore the physiological, protec-
tive functions of apoE.Introduction
Alzheimer’s disease (AD) is the most common cause of dementia
in the elderly. It is characterized clinically by progressive decline
in memory, executive function, language, and other areas of
cognition. Pathologically, there is formation of amyloid plaques
and neurofibrillary tangles in the brain, as well as neuronal loss,
synaptic loss, brain atrophy, and inflammation. Accumulation
of the amyloid-b (Ab) peptide, the major component of amyloid
plaques, is hypothesized to initiate a pathogenic cascade that
eventually leads to AD (Hardy and Selkoe, 2002). The sequential
proteolytic processing of amyloid b precursor protein (APP) by
b-secretase and g-secretase produces several Ab species,
including the most abundant 40 amino acid species (Ab40) and
a number of minor species, including Ab42 (Steiner and Haass,
2000). Ab is produced by all cells throughout life, with highest
levels made by neurons. The majority of extracellular Ab is gener-
ated through the endocytosis of APP into the endocytic
compartment, where both secretases can optimally produce
Ab (Cirrito et al., 2008; Koo and Squazzo, 1994). Although strong
genetic and biochemical evidence suggests that an increase in
total Ab production, an increase in the ratio of Ab42 to Ab40, or
generation of a mutant form of Ab with greater amyloidogenic
propensity are the main mechanisms for the rare early-onset
forms of autosomal-dominant familial AD, cerebral amyloid angi-
opathy (CAA), or a combination of both disorders, these are
probably not the major pathogenic mechanisms underlying the
more common late-onset AD (Haass and Selkoe, 2007; Tanzi
and Bertram, 2005). Defects in the clearance of brain Ab by
cellular uptake or transport across the blood-brain barrier might
underlie many cases of sporadic AD (Selkoe, 2001; Zlokovic,
2008). In addition, increased Ab aggregation influenced by Ab
binding molecules may also play an important role. Although
nongenetic environmental factors, such as education and
physical activity, may affect the risk of sporadic AD, twin studies
strongly suggest that genetic factors play a critical role in late-onset AD (Gatz et al., 2006). While many putative susceptibility
genes for AD have been reported, the only strongly confirmed
genetic risk factor across many studies for early and late-onset
AD is apolipoprotein E (APOE) genotype, with the 34 allele being
an AD risk factor and the 32 allele being protective (Corder et al.,
1993; Strittmatter et al., 1993a). Strong evidence suggests the
major mechanism by which apoE influences AD and CAA is via
its effects on Ab metabolism. However, the details of this
process as well as the role apoE plays in non-Ab-mediated
mechanisms in AD pathogenesis remain to be fully clarified.
Physiological Function of ApoE
The human apoE protein is a 299 amino acid glycoprotein with
variable levels of posttranslational sialylation through O-linked
glycosylation at the threonine 194 residue (Wernette-Hammond
et al., 1989). ApoE is expressed in several organs, with the highest
expression in the liver, followed by the brain. Nonneuronal cells,
mainly astrocytes and to some extent microglia, are the major
cell types that express apoE in the brain (Grehan et al., 2001; Pitas
et al., 1987). However, neurons can also produce apoE under
certain conditions, albeit at much lower levels than astrocytes
(Xu et al., 1999; Xu et al., 2006). ApoE functions as a ligand
in receptor-mediated endocytosis of lipoprotein particles. In
plasma, apoE proteins are present on lipoproteins in association
with other apolipoproteins, whereas in the brain apoE and two
other apolipoproteins, apoJ and apoA-1, are predominantly
present on distinct high-density-like lipoprotein particles (Fagan
et al., 1999; Pitas et al., 1987). Unlike plasma HDL that contains
apoA-1 as its major apolipoprotein, the predominant apolipopro-
tein of HDL in the central nervous system (CNS) is apoE
(Pitas et al., 1987). Although HDL-like lipoproteins are the only
lipoproteins in the central nervous system (CNS), their role in
CNS lipid and cholesterol homeostasis is not clearly defined.
After receptor-mediated endocytosis of apoE-containing lipo-
protein particles by low-density lipoprotein (LDL) receptor familyNeuron 63, August 13, 2009 ª2009 Elsevier Inc. 287
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cell surface (Rensen et al., 2000). Cholesterol released from
apoE-containing lipoprotein particles is used to support synapto-
genesis and the maintenance of synaptic connections (Pfrieger,
2003). Whether apoE-containing lipoproteins play a major role
in supporting synaptogenesis and maintenance of synaptic
connections in vivo in the uninjured brain has not yet been proven,
as several studies have shown that the brain of apoE knockout
mice for the most part appears normal in the absence of injury
(Anderson et al., 1998; Fagan et al., 1998).
Other Apolipoproteins in the Brain
In addition to apoE, several other apolipoproteins, including
apoA-I, apoA-II, apoA-IV, apoD, apoE, apoH, and apoJ, are
found in the brain. Among them, the potential roles of apoA-I
and apoJ in Ab fibrillogenesis and clearance have been investi-
gated (Ladu et al., 2000a). ApoA-I is the major apolipoprotein in
plasma HDL, mediating reverse cholesterol transport. Although
it is also found in the CSF, apoA-I is not synthesized in the brain
but transported across the blood-brain barrier (BBB). In contrast,
apoJ (also known as clusterin) is expressed in neurons and astro-
cytes, and its expression in astrocytes is strongly induced
following injury (Charnay et al., 2008). The presence of brain
apolipoproteins on distinct particles in the CNS may be due to
their differences in biogenesis. Both apoA-I and apoJ are known
to bind to Ab and prevent Ab aggregation and toxicity in vitro
(Ghiso et al., 1993; Koldamova et al., 2001; Paula-Lima et al.,
2009). However, such in vitro findings apparently contradict
with in vivo results obtained with apoa1 and apoj knockout
mice. ApoA-I deficiency did not alter amyloid pathology (Fagan
et al., 2004), while apoJ deficiency significantly reduced fibrillar
amyloid plaque formation and neuritic toxicity in a mouse model
of amyloidosis (DeMattos et al., 2002). More studies are required
to further elucidate the relative contribution of the effects of apoAI
and apoJ on Ab fibrillogenesis and metabolism in vivo.
Genetics of ApoE in AD
The human APOE gene contains several single-nucleotide poly-
morphisms (SNPs) distributed across the gene (Nickerson et al.,
2000). The most common three SNPs lead to changes in the
coding sequence and result in the three common isoforms of
apoE: apoE2 (cys112, cys158), apoE3 (cys112, arg158), and
apoE4 (arg112, arg158). Although the three common isoforms
differ by only one or two amino acids at residue 112 or 158, these
differences profoundly alter apoE structure and function (Mahley
et al., 2006). After immunoreactivity of apoE in amyloid plaques
was first reported (Namba et al., 1991; Wisniewski and Fran-
gione, 1992), the 34 allele of the APOE gene was discovered
to be a strong genetic risk factor for AD (Corder et al., 1993;
Strittmatter et al., 1993a). Since then, numerous studies have
confirmed that possession of the 34 allele is the strongest genetic
risk factor for both AD and CAA, or a combination of both disor-
ders (Bertram et al., 2007; Farrer et al., 1997). As compared to
individuals with no 34 alleles, the increased risk for AD is 2- to
3-fold in people with one 34 allele and about 12-fold in those
with two 34 alleles (Bertram et al., 2009; Roses, 1996). The
APOE 34 allele is also associated with an earlier age of AD onset
(Gomez-Isla et al., 1996; Roses, 1996). However, in certain288 Neuron 63, August 13, 2009 ª2009 Elsevier Inc.ethnic groups, the APOE 34 allele seems to have either a weaker
effect or no clear effect on AD (Farrer et al., 1997; Kalaria et al.,
2008; Mayeux, 2003; Tang et al., 1998). These results suggest
that other genetic and environmental factors may also contribute
to AD risk in certain ethnic groups. Finally, it is important to note
that the 32 allele of APOE is associated with a lower risk for AD
(Corder et al., 1994; Farrer et al., 1997).
While the effect of the 34 allele on the risk and age of onset for
AD is generally consistent in most studies, there have been
numerous conflicting reports regarding whether different APOE
alleles influence the rate of cognitive decline following dementia
onset (Asada et al., 1996; Craft et al., 1998; Frisoni et al., 1995;
Growdon et al., 1996; Hoyt et al., 2005; Kurz et al., 1996). Some
studies suggest that the effect of the 34 allele on cognitive decline
is stronger in the earlier clinical stages of disease and is weaker
during the later and more severe clinical stages (Cosentino
et al., 2008; Juva et al., 2000). Understanding whether apoE plays
a mechanistic role in the progression of AD is an important ques-
tion to address in the future and will provide further insights into its
pathophysiological role in AD. In addition, a more accurate
prediction of disease progression based upon 34 allele status
may allow for better clinical trial design. If the 34 allele does differ-
entially affect the progression and response to therapies, it will be
critical to subdivide subject groups and analyze the rate of cogni-
tive decline separately according to APOE genotype.
Effects of ApoE on Ab Aggregation
Human Studies
Although several reasons may underlie the APOE isoform-
specific effect on the risk of developing AD (Figure 1), convincing
evidence suggests that the physical interaction of apoE with Ab
Figure 1. Pathogenic Mechanisms of ApoE in Alzheimer’s Disease
Several mechanisms have been proposed to understand the differential
effects of apoE isoforms on AD pathogenesis. Evidence suggests that the
major effect of apoE isoforms on the risk of developing AD is via its effect on
Ab aggregation and clearance, influencing the onset of Ab deposition. Other
mechanisms, including the effects of apoE isoforms on synaptic function,
neurotoxicity, tau hyperphosphorylation, and neuroinflammation, may also
contribute to the disease process. Independent of APOE genotype, differ-
ences in the apoE levels and lipidation state may also mediate processes
involved in AD pathogenesis.
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association between apoE and Ab in the brain (Naslund et al.,
1995), it was hypothesized that apoE may function as an Ab-bind-
ing protein that induces a pathological b sheet conformational
change in Ab (Wisniewski and Frangione, 1992). Initial histopath-
ological studies investigating the relationship between amyloid
plaques and APOE isoforms demonstrated a positive correlation
between plaque density and APOE 34 allele dose (Rebeck et al.,
1993; Schmechel et al., 1993). However, several subsequent
studies reported conflicting findings (Benjamin et al., 1995;
Heinonen et al., 1995; Itoh and Yamada, 1996; Landen et al.,
1996b). Nonetheless, a more conclusive study with many more
subjects strongly suggested that APOE allele dosage is associ-
ated with increased neuritic plaques in AD (Tiraboschi et al.,
2004). Importantly, if the overall effect of apoE4 is to accelerate
the onset of Ab deposition into amyloid plaques, one would
expect to see the largest effect of apoE4 on brain amyloid depo-
sition in the late-middle-age period in subjects who are still cogni-
tively normal but who are ‘‘at risk’’ to develop AD. In fact, in a large
CSF study of cognitively normal middle-age people, CSF Ab42
was APOE 34-dose dependently lower (Sunderland et al.,
2004). Since people with brain amyloid deposition have low
CSF Ab42 (Fagan et al., 2006), this strongly suggests that amyloid
deposition on average is beginning earlier in apoE4-positive
subjects. This finding has now been confirmed more directly in
a study that showed cognitively normal subjects had an APOE
34 dose-dependent increase in fibrillar Ab burden in brain as de-
tected with an amyloid imaging agent (Reiman et al., 2009). On
the other hand, the effect of the apoE2 isoform on AD neuropa-
thology has not been thoroughly investigated, in part due to the
relative rarity of apoE2-positive participants. It remains unclear
whether apoE2 exerts its protective effect through modulating
Ab aggregation or an alternative mechanism that is independent
of amyloid plaque formation (Berlau et al., 2009).
In Vitro Ab Binding Studies
Following initial genetic and neuropathological findings from
human studies, many groups investigated the ability of apoE iso-
forms to bind Ab and subsequently influence its aggregation
process in vitro. Initially, it was demonstrated that lipid-free
apoE formed SDS-stable complexes with Ab and that apoE4
bound to Ab more rapidly than apoE3 (Sanan et al., 1994; Stritt-
matter et al., 1993b). However, subsequent studies reported
that lipid-associated apoE2 and apoE3 formed SDS-stable
complexes with Ab to a much greater extent than apoE4 (Alesh-
kov et al., 1997; LaDu et al., 1994; Yang et al., 1997). Most studies
demonstrate that the efficiency of complex formation between
lipidated apoE and Ab follows the order of apoE2 > apoE3 >>
apoE4 (Tokuda et al., 2000). Since the binding efficiency of
apoE isoforms to Ab correlates inversely with the risk of devel-
oping AD, it has been hypothesized that apoE2 and apoE3 may
enhance the clearance of Ab, compared to apoE4. Residues
12–28 of Ab appears to contain the binding site for apoE (Stritt-
matter et al., 1993a, 1993b), and this region has been used to
block the interaction between apoE and Ab (Ma et al., 1996;
Sadowski et al., 2006).
In Vitro Ab Aggregation Studies
Given the strong genetic evidence and the isoform-specific
difference in the interaction of apoE with Ab, the effect of apoEisoforms on Ab aggregation has been investigated extensively
in vitro. One study demonstrated that all three apoE isoforms
promoted Ab42 fibrillization, with the effect being more enhanced
with the apoE4 isoform and least with apoE2 (Ma et al., 1994).
Subsequently, others also found that apoE4 was more efficient
than apoE3 at increasing Ab40 aggregation (Castano et al.,
1995; Wisniewski et al., 1994). These findings are apparently
consistent with the increased amyloid plaque load in subjects
with theAPOE 34 allele. However, human genetic and histological
data do not exclude the possibility that all three apoE isoforms are
inhibitors of Ab aggregation, with apoE4 being the least effective
at inhibition. Indeed, other studies reported that human apoE iso-
forms decreased Ab fibrillogenesis in vitro by interfering with Ab
nucleation (Beffert and Poirier, 1998; Evans et al., 1995; Webster
and Rogers, 1996; Wood et al., 1996). Conflicting results between
numerous in vitro studies may be due to the differences in apoE
and Ab preparations or other factors discussed below.
Difference in apoE Preparations
The formation of heterogeneous multimeric forms of apoE, the
diverse assembly states of apoE, and the variable levels of oxida-
tion in apoE may affect the binding properties of apoE to Ab and
other apoE binding proteins, including apoE receptors. More
importantly, the different extent of apoE lipidation seems likely
to be responsible for the contradictory results among various
in vitro studies. Since considerable conformational differences
exist between lipid-free and lipid-bound forms of apoE (Blacklow,
2007), the presence of lipids leads to alterations in the binding
properties of apoE with Ab as well as other proteins (Dergunov
et al., 2000; Ljungberg et al., 2003). Since most in vitro studies
have used nonphysiological preparations of lipid-free apoE, the
implications of such findings to the in vivo environment remain
uncertain. It is more desirable to use apoE prepared in a condition
that preserves its native lipoprotein particle structure found in the
brain to best understand its role in the CNS and in Abmetabolism.
Ab40 versus Ab42
Several recent studies suggest that Ab40 and Ab42 may have
opposing effects on Ab aggregation in vivo (Kim et al., 2007;
McGowan et al., 2005). Given these emerging data, results from
Ab40 in vitro aggregation experiments may need to be interpreted
somewhat differently. Interestingly, there have been several
reports suggesting that Ab40 preferentially aggregates in an
APOE 34 gene dose-dependent manner in AD subjects (Gearing
et al., 1996; Ishii et al., 1997; Mann et al., 1997). Although the
apparent differential effects on Ab40 and Ab42 aggregation by
apoE4 might be simply attributed to the increased CAA in apo34
subjects, careful immunohistochemical analyses of plaques
using Ab40- or Ab42-specific antibodies suggest that increased
CAA in 34-positive subjects does not entirely account for the pref-
erential Ab40 deposition (Gearing et al., 1996; Mann et al., 1997). It
is conceivable that ApoE4 may be able to induce a conformational
change in Ab40, which either renders it into an Ab42-like structure
or generates a distinctly polymorphic ApoE4-Ab40 complex with
higher aggregation propensity. The differential effects on Ab
aggregation by apoE isoforms warrant further investigation.
Differences in Ab Preparations and Aggregation
Conditions
Inconsistent reports regarding the effect of apoE on Ab aggrega-
tion may also be attributable to the inherent issues with syntheticNeuron 63, August 13, 2009 ª2009 Elsevier Inc. 289
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lag time and rate of aggregation, can vary considerably between
apparently identical samples due to the use of starting materials
that contain heterogeneous mixtures of monomers and oligo-
mers. Since apoE isoforms have differential binding affinities to
different aggregation intermediates, it is critical to use well-
defined single Ab species as a starting material. One of the
most critical parameters is the concentration of Ab and apoE
used in the aggregation assay. Almost all Ab in vitro fibrillogene-
sis experiments with apoE isoforms have been performed with
nonphysiologically high micromolar concentrations of Ab. Such
high concentrations may artificially cause Ab40 to aggregate
without an Ab42 seeding nucleus, despite the fact that Ab40
has an anti-amyloidogenic effect in vivo (Kim et al., 2007). There-
fore, the in vivo implication of findings from such nonphysiolog-
ical conditions is not clear. Most importantly, nearly all studies
have used a high molar ratio of Ab to apoE, in vitro conditions
that are opposite to what is found in vivo where the apoE/Ab
molar ratio is 10–30. To better understand the effect of apoE
isoforms on Ab aggregation, further experiments should be per-
formed with apoE and Ab prepared to match in vivo conditions.
In Vivo Animal Data
Although in vitro studies investigating the interaction between
apoE and Ab have been informative, the in vivo environment
surrounding apoE and Ab in the brain may be very different
from the artificial settings of in vitro experiments. Initial studies
using the PDAPP and Tg2576 APP-transgenic mouse models
that develop Ab deposition demonstrated that the lack of murine
apoE resulted in a significant decrease in Ab deposition, along
with an almost complete lack of true amyloid plaques and
neuritic dystrophy (Bales et al., 1997; Holtzman et al., 1999,
2000). Furthermore, in the PDAPP mouse model, the anatomical
pattern of Ab deposition was markedly different (Fagan et al.,
2002; Irizarry et al., 2000). These results make it evident that
mouse apoE plays a significant role in both the extent and distri-
bution of Ab deposition, along with its associated damage to
neurites. Following these initial studies with apoE knockout
mice, several lines of transgenic mice were generated to study
the role of human apoE isoforms in AD pathogenesis (Raber
et al., 1998; Sun et al., 1998; Xu et al., 1996). The expression of
human apoE isoform transgenes in PDAPP mice resulted in
a marked delay in the deposition of Ab and formation of neuritic
plaques, compared to PDAPP mice expressing murine apoE or
no apoE (Fagan et al., 2002; Holtzman et al., 1999, 2000). Inter-
estingly, the human apoE-transgenic mice display an isoform-
specific pattern of Ab deposition in the hippocampus, with
apoE4 mice having increased levels of Ab deposits and more thi-
oflavine-S-positive plaques than apoE3 mice (Fagan et al., 2002;
Holtzman et al., 2000). Other studies using transgenic mice that
possess different human apoE transgenes also demonstrate an
isoform-specific difference (E4 > E3) in Ab deposition (Buttini
et al., 2002; Dolev and Michaelson, 2004).
Although transgenic mouse models have been useful for
investigating the role of human apoE isoforms in AD, the gener-
ation of apoE knockin mice that express human apoE isoforms
under the control of endogenous mouse regulatory elements
allows one to examine the role of each isoform under more phys-
iological conditions (Hamanaka et al., 2000; Sullivan et al., 1997,290 Neuron 63, August 13, 2009 ª2009 Elsevier Inc.1998). When apoE3 and apoE4 knockin mice were bred to the
Tg2576 mice, apoE3 and apoE4 delayed the onset of Ab depo-
sition relative to mouse apoE, and apoE4 mice had significantly
more amyloid deposition and CAA than apoE3 mice (Fryer et al.,
2005b). Recently, PDAPP mice bred to apoE2, E3, and apoE4
knockin mice demonstrated a clear isoform-dependent (E4 >
E3 > E2) effect on Ab accumulation (Bales et al., 2009). It is clear
that elucidating what the underlying in vivo mechanisms are for
the apoE isoform-mediated difference in Ab accumulation is crit-
ical for relating these findings to the pathogenesis of AD.
Several key questions remain to be further addressed using
in vivo models that develop Ab accumulation. The somewhat
rudimentary but important question still exists as to whether it
is better to increase or decrease human apoE levels (regardless
of isoform) in order to reduce Ab levels. A preliminary study
suggests that APP-transgenic mice heterozygous for apoE3
have more deposited Ab in the brain in comparison to mice with
two copies of the apoE3 allele (DeMattos, 2004). In addition, intra-
cerebral administration of a lentivirus expressing human apoE2
into the brains of PDAPP mice has shown that gene delivery strat-
egies may be useful in decreasing Abburden (Dodart et al., 2005).
Analyzing whether, and to what extent, altering human apoE level
affects Ab pathology will help determine whether targeting apoE
levels may be a viable therapeutic option for influencing Ab levels
and toxicity, and ultimately treating AD.
Effects of ApoE on Ab Clearance
In addition to the effects on fibrillogenesis, there is evidence that
apoE alters both the transport and metabolism of Ab in the brain.
The effects of apoE isoforms on APP processing and Ab produc-
tion have been investigated in cell culture systems. A few studies
suggest that lipid-poor and lipid-free apoE4 enhance Ab produc-
tion by increasing LRP1- and ApoER2-mediated APP endocy-
tosis (He et al., 2007; Ye et al., 2005). However, others found
no clear evidence for isoform-specific effects on APP processing
(Biere et al., 1995; Cedazo-Minguez et al., 2001; Irizarry et al.,
2004). In addition, there is no convincing data suggesting apoE
isoforms have differential effects on the production of Ab
in vivo. Regardless of its effect on Ab production, apoE seems
to play an important role in the clearance of Ab through several
plausible mechanisms (Figure 2). ApoE-containing lipoprotein
particles may sequester Ab and modulate the cellular uptake of
an apoE-Ab complex by receptor-mediated endocytosis. Alter-
natively, apoE may modulate Ab removal from the brain to the
systemic circulation by transport across the blood-brain barrier.
Several in vitro studies have demonstrated that human apoE
facilitates the binding and internalization of soluble Ab by various
types of neuronal cells (Beffert et al., 1998, 1999a; Cole and Ard,
2000; Nielsen et al., 2008; Yamauchi et al., 2000, 2002; Yang
et al., 1999). Though some of these studies did observe apoE
isoform-dependent differences in the extent of Ab cellular
uptake, no overall trend emerged. Two in vitro studies have
also demonstrated that apoE can facilitate the cellular degrada-
tion of Ab (Jiang et al., 2008; Koistinaho et al., 2004). However,
more studies are necessary to solidify whether apoE facilitates
the uptake of Ab into the various cell types found in the brain,
whether this enhanced uptake occurs in an isoform-specific
manner, and by what mechanism this may occur.
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and Deposition
ApoE is primarily produced by both astrocytes
and microglia and is subsequently lipidated by
ABCA1 to form lipoprotein particles. In the extra-
cellular space, lipidated apoE binds to soluble Ab
in an isoform-dependent pattern (E2 > E3 > E4)
and influences the formation of parenchymal
amyloid plaques and transport of Ab within the
CNS. ApoE is endocytosed into various cell types
within the brain by different members of the LDL
receptor family, including LDLR and LRP1. ApoE
may also facilitate the cellular uptake of Ab
through the endocytosis of a complex of apoE-
containing lipoprotein particles bound to Ab in
a manner that likely depends upon the isoforms
and its level of lipidation. Furthermore, apoE has
been shown to directly enhance both the degra-
dation of Ab within microglial cells and the ability
of astrocytes to clear diffuse Ab deposits (Jiang
et al., 2008; Koistinaho et al., 2004). Ab associ-
ated with apoE-containing lipoprotein particles
may also be retained within the CNS through their
binding to heparin sulfate proteoglycan (HSPG)
moieties present in the extracellular space (Mah-
ley and Rall, 2000). At the BBB, soluble Ab is
predominantly transported from the interstitial
fluid into the bloodstream via LRP1 and P-glyco-
protein (Cirrito et al., 2005; Zlokovic, 2008).
ApoE has been shown to slow the transport of
Ab across the BBB in an isoform-dependent
manner (E4 > E3 > E2) (Bell et al., 2007; Deane et al., 2008; Ito et al., 2007). In addition, apoE can influence the pathogenesis of CAA in an APP-transgenic
mouse model, with apoE4 increasing the amount of vascular plaques in comparison to apoE3 (Fryer et al., 2005b).An issue that remains unclear is how these in vitro results
relate to what has been observed in the in vivo environment,
where apoE deficiency leads to a dramatic reduction in thiofla-
vin-S-positive amyloid load (Bales et al., 1997, 1999; Holtzman
et al., 1999). Interestingly, it has been shown in young
PDAPP mice prior to the onset of Ab deposition, that the lack
of apoE may actually increase soluble Ab levels, a finding that
is consistent with cell culture data (Dodart et al., 2002; Fagan
et al., 2002). This result was also demonstrated in a study
where in vivo microdialysis was used to analyze the level of
Ab in brain interstitial fluid (ISF) (DeMattos et al., 2004). While
some publications support the in vitro studies that suggest
apoE enhances cellular Ab uptake and degradation, one must
also consider the blood-brain barrier as a potential pathway
of Ab clearance in the brain, especially via LRP1 (Zlokovic,
2008).
In the presence of human apoE, the in vivo clearance of Ab has
not been extensively studied. A recent study has shown that the
brain to blood clearance of lipidated apoE4 in the mouse brain is
significantly lower than the clearance of apoE3 and apoE2
(Deane et al., 2008). Interestingly, this trend is opposite for
what is observed for the total brain levels of human apoE when
the human apoE is produced in apoE knockin mice. Therefore,
whether the BBB plays a major role in regulating the levels of
apoE in the brain needs to be further verified. Accumulating
recent evidence strongly suggests that when human apoE is
complexed with Ab, the brain to blood clearance of Ab is actually
decreased compared to that of free Ab (Bell et al., 2007; Deane
et al., 2008; Ito et al., 2007). Furthermore, Ab complexed to
apoE2 and apoE3 is cleared out of the brain at a significantly
faster rate than Ab complexed to apoE4 (Deane et al., 2008).However, another study using different methods also looking
at BBB transport of Ab in mice expressing transgenes for either
human apoE3 or apoE4 did not show any differences in the clear-
ance of Ab from the brain (Ji et al., 2001). Finally, an apoE4-Ab
complex present in the periphery is sequestered into brain capil-
laries to a greater extent than Ab bound to apoE2 or apoE3,
demonstrating that apoE4-mediated blood to brain transport of
Ab may play a role in amyloid accumulation in the brain (Martel
et al., 1997). Despite these findings, more work is needed to
determine the exact role that the BBB plays in mediating Ab
clearance, how apoE plays a role in this process, and whether
isoform-specific effects exist.
ApoE Levels in the Central Nervous System
ApoE Levels between AD Cases and Controls
Given the strong effect of APOE alleles on the risk of developing
AD, there have been numerous studies investigating if apoE
protein levels are associated with AD. Previous studies of CSF
apoE levels in humans provided no clear consensus on this
question (Landen et al., 1996a; Lefranc et al., 1996; Lehtimaki
et al., 1995; Lindh et al., 1997; Mulder et al., 1998; Sihlbom
et al., 2008). To minimize confounding factors, such as the differ-
ence in CSF collection methods and severity of disease, a subse-
quent study classified a large number of subjects according to
clinical dementia rating (CDR) and analyzed apoE protein level
in CSF collected in a standardized manner (Wahrle et al.,
2007). The levels of CSF apoE were not significantly different
between cognitively normal subjects (CDR 0) and those who
had very mild (CDR 0.5) or mild-moderate dementia (CDR 1-2).
The relationship between apoE levels in CSF and brain paren-
chyma is not well studied yet.Neuron 63, August 13, 2009 ª2009 Elsevier Inc. 291
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Although there have been many studies trying to understand the
differential effects of apoE isoforms on AD pathogenesis, it is
possible that the observed phenotypes are, in part, mediated
by the difference in the levels of apoE proteins in the brain
between isoforms. Such differences in the amount of apoE could
modulate the risk for AD, as it has been demonstrated for the risk
of cardiovascular mortality (Mooijaart et al., 2006). A number of
studies investigating apoE protein levels in the brain and CSF
in correlation with APOE genotypes have generated inconsistent
results. One study reported that apoE4 accounted for 60%–70%
of the total apoE protein in CSF from 33/34 heterozygote
subjects, which contrasted with the lower proportion of apoE4
in plasma (Fukumoto et al., 2003). However, earlier studies
found that CSF apoE concentrations did not vary among
different apoE isoforms (Landen et al., 1996a; Lehtimaki et al.,
1995). More recent studies also report that CSF apoE concentra-
tions, measured by apoE ELISA and nephelometry, do not signif-
icantly differ among subjects with different apoE isoforms (Bekris
et al., 2008; Wahrle et al., 2007).
Levels of apoE Isoforms in the Brain Parenchyma
A number of studies investigating apoE expression and protein
levels in the brain parenchyma as a function of APOE genotype
have yielded controversial results (Beffert et al., 1999b; Bertrand
et al., 1995; Bray et al., 2004; Growdon et al., 1999; Harr et al.,
1996; Lambert et al., 1997; Pirttila et al., 1996). The conflicting
results from brain parenchyma studies may stem from the
relatively small sample size and heterogeneity in subject popula-
tion, with subjects at different stages and duration of disease.
Since apoE expression is transcriptionally induced by Ab and
increases with glial activation, duration and severity of disease
may considerably affect apoE mRNA and protein levels. In addi-
tion, apoE levels may be artificially altered by postmortem delay
(Pirttila et al., 1996). If the effect of apoE isoforms is to influence
whether and when Ab deposits, the most important time to
measure it in the brain samples would be prior to the onset of
Ab deposition. This will be technically very difficult to accomplish
in humans. Most importantly, prospective longitudinal studies
with healthy nondemented subjects will be very informative in
testing whether levels of CSF apoE, independent of APOE geno-
type, are associated with the risk of developing AD.
Mouse Data
In general, human studies have certain limitations that preclude
the precise analysis of apoE levels in the CNS. Thus, attention
has been devoted to better characterizing apoE levels in the
brain and CSF of human apoE knockin mice (Hamanaka et al.,
2000; Sullivan et al., 1997, 2004). Because these mice express
apoE under the endogenous mouse apoe promoter, protein
levels should reflect the natural synthesis and metabolic rates
of apoE in the mouse CNS. An initial study characterizing such
mice suggested that apoE levels in the mouse brains were not
significantly different among the apoE2, apoE3, and apoE4
isoforms (Sullivan et al., 2004). However, several subsequent
studies were able to detect a genotype-dependent difference
in apoE levels (E2 > E3 > E4) in the brain and CSF of apoE
knockin mice (Fryer et al., 2005a; Mann et al., 2004; Ramaswamy
et al., 2005; Riddell et al., 2008; Vitek et al., 2007). If more studies
confirm that an isoform-dependent difference in apoE levels is292 Neuron 63, August 13, 2009 ª2009 Elsevier Inc.present in the brains of both humans and mice, it will be impor-
tant to determine why such a phenomenon is observed. One
possibility is that the clearance or degradation of apoE4 is
elevated in the CNS relative to other apoE isoforms. This may
be due to either differential binding of apoE isoforms to members
of the LDLR family or an intrinsic property of the apoE4 protein
structure that affects its stability in the CNS. Interestingly,
a recent in vitro study has shown that apoE4 is degraded more
quickly than apoE2 or apoE3 in primary mouse astrocyte
cultures (Riddell et al., 2008). It will be important to determine
whether the clearance rates of apoE isoforms are different in
an in vivo setting. It is also necessary to directly determine
whether differences in apoE levels account for any effect apoE
has on AD pathogenesis, as this may lead to the development
of future AD therapeutics that directly target the level or stability
of the apoE protein.
LDL Receptor Family Members
Given the physical interaction between apoE and Ab, apoE-
containing lipoprotein particles might alter the metabolic fate
of Ab. Since apoE-mediated Ab clearance may be modulated
by several apoE binding proteins, the potential roles of LDL
receptor family members and ATP-binding cassette transporter
A1 (ABCA1) in AD pathogenesis have been studied extensively
(Figure 2).
Lipoprotein Receptor-Related Protein 1
LRP1 functions as an endocytic and signaling receptor with
a wide expression pattern in a variety of tissues. The ligands
for LRP1 include several proteins already implicated in AD path-
ogenesis, such as apoE, APP, Ab, a2-macroglobulin, matrix met-
allopeptidase 9, and tissue-type plasminogen activator (Herz
and Bock, 2002). LRP1 has been proposed to affect pathogen-
esis of AD by regulating Ab catabolism and APP processing
(Cam and Bu, 2006). Recently, Bu and colleagues developed
conditional LRP1 forebrain knockout mice by crossing LRP1
floxP mice with aCamKII-Cre mice (Liu et al., 2007). A series of
mechanistic studies suggested that APP intracellular domain
(AICD) interacts with the LRP1 promoter and suppresses its
transcription. However, a subsequent study did not support
a role of AICD in the transcriptional regulation of LRP1 (Tamboli
et al., 2008). In contrast to the previous study, loss of g-secretase
function impaired endocytosis of LDLR by interfering with
subcellular trafficking of adaptor proteins Fe65 and autosomal-
recessive hypercholesterolemia protein. Since the reasons for
the conflicting findings remain unclear, the effects of g-secretase
on expression and processing of lipoprotein family members
need to be further investigated.
Low-Density Lipoprotein Receptor
LDLR is a cell surface glycoprotein that plays an important role
in mediating the removal of cholesterol and cholesteryl ester-
containing low-density lipoprotein (LDL) particles from the
circulation (Brown and Goldstein, 1986; Herz and Bock, 2002).
Association of apoE with lipid is required for its high-affinity
binding to LDLR (Blacklow, 2007). Compared with the other iso-
forms, apoE2 has only 1%–2% of binding affinity to LDLR and its
presence is associated with hyperlipidemia in some apoE2 indi-
viduals (Ruiz et al., 2005). Direct evidence demonstrating LDLR
as one of the main apoE receptors in the brain was provided
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knockin mice (Fryer et al., 2005a). While the effects of LRP1 on
APP and Ab have been thoroughly investigated, the potential
implication of LDLR in AD pathogenesis has not been extensively
studied. Interestingly, a couple of SNPs in the LDLR gene were
found to be associated with a risk of AD in a gender-specific
manner (La¨msa¨ et al., 2008; Zou et al., 2008). In addition,
LDLR deficiency was associated with increased amyloid deposi-
tion in Tg2576 APP-transgenic mice (Cao et al., 2006). In
contrast, another study using PDAPP-transgenic mice demon-
strated that there was no alteration in Ab levels at both a young
and old age by biochemical analyses, although there was a trend
toward increased amyloid burden in the absence of LDLR (Fryer
et al., 2005a). It remains unknown whether increased levels or
function of LDLR would have a direct effect on Ab clearance or
amyloid formation in vivo. Such knowledge will be critical to eval-
uate whether the modulation of LDLR expression and its stability
can be exploited as a therapeutic target.
Lipoprotein Receptor with 11 Binding Repeats (LR11,
also Known as Sorting Protein-Related Receptor with
LDLR Class A-Type Repeats SorLA or SorL1)
LR11/SorLA was initially identified as a novel receptor capable of
binding to the LRP-1 ligand receptor-associated protein (RAP)
(Jacobsen et al., 1996). In addition to the ligand-binding comple-
ment-type repeats found in other LDL receptor family members,
LR11/SorLA also has a vacuolar protein sorting 10 protein
(vps10p) domain that is implicated in intracellular protein traf-
ficking. Therefore, LR11/SorLA is considered as a unique hybrid
protein that belongs to both the vps10p domain receptor family
and the LDL receptor family. LR11/SorLA is predominantly
expressed in neurons (Motoi et al., 1999). Its role in AD patho-
genesis was initially suggested after the discovery of lower
levels of LR11/SorLA expression in patients with sporadic AD
(Scherzer et al., 2004) and mild cognitive impairment (Sager
et al., 2007). Genetic association of LR11/SorLA variants with
AD further corroborates its mechanistic link to AD pathogenesis
(Rogaeva et al., 2007). LR11/SorLA sequesters APP in the trans-
Golgi network, decreasing the amount of APP in post-Golgi
compartments and the plasma membrane (Andersen et al.,
2005; Schmidt et al., 2007). Consistent with the previous cell-
based studies, reduction of LR11/SorLA protein levels increased
Ab levels and exacerbated amyloid plaque pathology in an APP/
PSEN1D9 mouse model of amyloidosis (Dodson et al., 2008).
Given such findings, it will be important to understand the factors
that regulate LR11/SorLA protein levels.
Apolipoprotein Receptor 2 (ApoER2, also Known
as LRP8)
ApoER2 is another member of the LDL receptor family that is
highly expressed in the brain (Herz and Chen, 2006). Along with
VLDLR, ApoER2 plays critical roles in neuronal migration and
brain development by functioning as a receptor for reelin (Herz
and Chen, 2006). ApoER2 also interacts with F-spondin through
its extracellular ligand-binding complement-type repeats (Hoe
et al., 2005b). F-spondin may function as a linker between
ApoER2 and APP through its interaction with extracellular and
intracellular domains of APP (Ho and Sudhof, 2004). Interactions
of ApoER2 with APP are known to affect APP processing, leading
to the increased production of Ab (Fuentealba et al., 2007; Heet al., 2007). However, it is not clear whether interactions between
apoE and apoER2 in the CNS regulate apoE levels or function
in vivo.
ATP-Binding Cassette Transporter A1
ATP-binding cassette A1 (ABCA1) is a cholesterol transporter
widely expressed in several tissues, including the brain. It
transports cellular cholesterol and phospholipids from cells to
lipid-poor apolipoproteins, including apoE, in order to form
high-density lipoproteins (HDL) (Figure 2) (Lawn et al., 1999).
Defects in theABCA1 gene cause Tangier disease, which is char-
acterized by HDL deficiency in plasma, accumulation of choles-
teryl esters in lymphatic tissue, peripheral neuropathy, and an
increased risk for cardiovascular disease (Bodzioch et al.,
1999; Brooks-Wilson et al., 1999; Rust et al., 1999). Because of
its role in maintaining adequate cholesterol homeostasis and
distribution, ABCA1 has gained attention as being an important
protein target for both AD pathogenesis and treatment. Mouse
studies have proven useful in clearly demonstrating an effect
of ABCA1 on Ab pathology. As expected, apoE from abca1
knockout mice was very poorly lipidated both in the periphery
and in the brain, compared to wild-type mice. Genetic deletion
of abca1 led to a significant reduction in steady-state apoE
protein levels in the brain and CSF as well as in the plasma
(Hirsch-Reinshagen et al., 2004; Wahrle et al., 2004), suggesting
that poorly lipidated apoE is more rapidly catabolized. Due to the
decreased levels of apoE, it was hypothesized that the lack of
ABCA1 would lead to a decrease in Ab deposition and amyloid
formation in human APP mouse models. However, three inde-
pendent studies demonstrated that ABCA1 deficiency leads to
an increase in both Ab and amyloid load in the brains of three
different transgenic APP mouse models (Hirsch-Reinshagen
et al., 2005; Koldamova et al., 2005; Wahrle et al., 2005). Abca1
deletion did not have an effect on Ab production (Koldamova
et al., 2005; Wahrle et al., 2005), suggesting that the presence
of poorly lipidated apoE somehow promotes the formation of
amyloid fibrils. A recent in vitro study demonstrated that the pres-
ence of fully lipidated apoE was necessary for effective degrada-
tion of Ab in microglia, suggesting that ABCA1 affects Ab clear-
ance via apoE (Jiang et al., 2008). The effect of increasing the
level of ABCA1 in the mouse brain has also been investigated
through the use of ABCA1-transgenic mice. When these mice,
which had greater apoE lipidation, were crossed with PDAPP
mice, there was a dramatic decrease in the amount of Ab depo-
sition and thioflavine-S-positive plaques in the ABCA1-trans-
genic mice (Wahrle et al., 2008). These data suggest that
increasing the lipidation state of apoE may influence either the
metabolism of Ab in the mouse brain or the ability of Ab to form
amyloid fibrils.
The Effect of ApoE on Synaptic Plasticity and Cognition
In Vitro Studies
In the peripheral and central nervous systems, the level of apoE
increases following neuronal injuries. It has been hypothesized
that such a surge of apoE may be required for repair of the
nervous system by redistributing lipids and cholesterols for
membrane repair and synaptic plasticity (Slezak and Pfrieger,
2003). Indeed, a number of studies suggest that apoE isNeuron 63, August 13, 2009 ª2009 Elsevier Inc. 293
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particularly in vitro (Figure 1). The neurite outgrowth phenotype
modulated by apoE isoforms is the most extensively studied in
this regard. Most studies have shown that apoE3 augments
neurite outgrowth to a greater extent than apoE4 (Bellosta
et al., 1995; Nathan et al., 1994, 2002; Sun et al., 1998; Teter
et al., 1999). However, the effect of apoE4 on neurite outgrowth
has been inconsistent among studies (DeMattos et al., 1998;
Puttfarcken et al., 1997; Teter et al., 2002). The relative effect
of the apoE2 isoform on neurite sprouting has not been thor-
oughly examined in most studies. The differences in cell types,
lipid source, and growth factors in cell culture media might
contribute some of the discrepancies between studies. The stim-
ulation of neurite outgrowth by apoE may be mediated by LRP1
(Fagan et al., 1996; Holtzman et al., 1995; Narita et al., 1997; Na-
than et al., 2002) or other apoE receptors (DeMattos et al., 1998;
Puttfarcken et al., 1997). The isoform-specific effect of apoE on
neurite outgrowth could be secondary to its effect on microtu-
bule organization, since the inhibitory effect of apoE4 on neurite
outgrowth was closely associated with its detrimental effect on
microtubule stability (Nathan et al., 1995).
In Vivo Studies
Although the mechanisms by which apoE exerts isoform-
specific differences on neurite outgrowth in vitro are interesting,
it is critical to understand whether such findings are relevant
in vivo. Some results obtained from in vivo studies appear to
be consistent with in vitro findings. Compared with apoE3-trans-
genic mice, apoE4-transgenic mice had impaired compensatory
sprouting and synaptogenesis after entorhinal cortex lesion
(White et al., 2001) and were more severely impaired in learning
and memory (Hartman et al., 2001; Raber et al., 1998, 2000).
Some phenotypic differences observed with apoE-transgenic
mouse models have been replicated with apoE knockin mouse
models (Bour et al., 2008; Grootendorst et al., 2005; Trommer
et al., 2004; Wang et al., 2005). In the presence of high levels
of Ab and APP, several studies have also demonstrated that
apoE isoforms have differential effects on synaptic plasticity
and cognition, even independent of plaque formation. Male
apoE4 mice had significant deficits in spatial memory, whereas
apoE3 prevented Ab- or APP-induced cognitive impairment
(Raber et al., 2000). Support for the neuroprotective function of
apoE2 against Ab-mediated toxicity came from a study where
apoE2-transgenic mice were bred with two different kinds of
APP-transgenic mice (Lanz et al., 2003). Dendritic spine loss
observed in the hippocampus of young APP-transgenic mice
was ameliorated by apoE2 overexpression. While almost all
in vivo studies have found that apoE3 augmented synaptic plas-
ticity and exerted neuroprotective effects to a greater extent,
compared with apoE4, the effects of apoE4 on synaptic plasticity
were inconsistent among studies. Some studies propose that
apoE4 has negative effects on neurites and synaptic functions
(Cambon et al., 2000), whereas other findings suggest minor
beneficial effects in apoE4 mice compared with apoE knockout
mice (Masliah et al., 1997; Veinbergs et al., 1999). Such conflict-
ing observations from animal studies appear to reflect the incon-
sistent results obtained from in vitro experiments. In addition,
findings from human subjects are not conclusive in regard to
the effects of apoE on neuronal processes (Arendt et al., 1997;294 Neuron 63, August 13, 2009 ª2009 Elsevier Inc.Schonheit et al., 2007). Further studies are warranted to deter-
mine whether there are apoE isoform-specific differences in
synaptic structure and cognitive functions from subjects without
obvious AD-related pathology.
The Role of ApoE in Neurotoxicity
In addition to modulating synaptic function, apoE4 may
contribute to neuronal degeneration processes either by direct
neurotoxicity or by indirectly potentiating detrimental effects of
other insults, such as high levels of Ab (Figure 1). One of the
most extensively investigated direct toxic mechanisms involves
the 29 kDa carboxyl-terminal-truncated fragment of apoE4
(amino acid 1–272 residues) (Mahley et al., 2007; Mahley et al.,
2006). The 29 kDa amino-terminal fragment generated by
chymotrypsin-like serine protease has been shown to induce
cytoskeletal disruptions and perturb mitochondrial energy
balance. Additionally, the 22 kDa amino-terminal fragment
produced by thrombin cleavage (amino acid 1–191 residues)
also has neurotoxic effects (Tolar et al., 1999). Since the exis-
tence of 22 kDa apoE fragments in the human brain has not
been conclusively demonstrated, the relevance of the thrombin
cleavage fragment to AD pathogenesis remains unclear. Along
with Ab-independent intrinsic toxicities, apoE4 has been shown
to exacerbate neurotoxicity triggered by Ab and other insults
(Mahley et al., 2006). Whether apoE amino-terminal fragments
play a role in the brain in vivo is not yet clear and further studies
are required to define its potential role in the normal brain and in
AD pathogenesis.
The Effect of ApoE Isoforms on Tau
Along with amyloid plaque formation, hyperphosphorylation of
the microtubule-binding protein tau and subsequent formation
of neurofibrillary tangles are hallmarks of AD pathology. The rela-
tionship between apoE and tau has not been thoroughly investi-
gated and the results are much less clear than the association
between APOE 34 allele dose and amyloid plaque burden.
Although some studies reported a positive relationship between
the neurofibrillary tangle density and APOE 34 allele dosage
(Ghebremedhin et al., 1998; Nagy et al., 1995; Ohm et al.,
1995; Polvikoski et al., 1995), others found no clear correlation
(Itoh and Yamada, 1996; Landen et al., 1996b; Morris et al.,
1995; Olichney et al., 1996; Oyama et al., 1995). Unlike studies
with human subjects, data from in vitro and animal models
appear to be more consistent among studies. Under in vitro
conditions, apoE3 binds tightly to tau and forms an SDS-stable
complex through the interaction of the N-terminal domain of
apoE3 and the microtubule-binding repeat regions of tau,
whereas apoE4 does not interact significantly with tau (Strittmat-
ter et al., 1994). The interaction between apoE3 and tau was
prevented by the phosphorylation of tau, suggesting that
apoE3 binds preferentially to nonphosphorylated tau. However,
there is currently no conclusive evidence demonstrating localiza-
tion of apoE to the neuronal cytosol, where the majority of tau
exists under normal conditions (DeMattos et al., 1999). There-
fore, the physiological relevance of the direct interaction
between apoE and tau remains to be determined. Of note,
more recent data suggests the possibility that a fragment of
apoE4 (1–272 amino acids), but not full-length apoE4, escapes
Neuron
Reviewthe secretory pathway, translocates to the cytosolic compart-
ment, and interacts with cytoskeletal components, including
tau and neurofilament (Chang et al., 2005). Alternatively, the
effects of apoE on tau phosphorylation could be explained by
an intracellular signaling pathway induced by apoE (Harris
et al., 2004; Hoe et al., 2005a), rather than the direct interaction
between apoE and tau. Although in vitro studies have provided
some insights, in vivo studies proving whether an apoE-isoform
dependent effect on tau even exists will be critical.
The Role of ApoE in Neuroinflammation
Inflammation and apoE
Abnormal activation of astrocytes and microglia are common
pathological features of many neurodegenerative diseases.
Along with amyloid plaques and neurofibrillary tangles, promi-
nent activation of innate inflammatory responses is also
observed in the brains of AD patients. Such neuroinflammation
is generally believed to contribute to the pathogenesis of AD
(Figure 1) (Bales et al., 2000). Activated glial cells are closely
associated with amyloid plaques, suggesting that plaques or
soluble forms of Ab around plaques, may induce inflammatory
cascades. Consistent with neuropathological findings, Ab is
shown to trigger glial neuroinflammatory responses in cell
culture systems (Hu et al., 1998). Interestingly, Ab induces the
production of apoE and the increased levels of apoE limit
Ab-driven neuroinflammation, possibly functioning as a feedback
mechanism (Guo et al., 2004; LaDu et al., 2001). In addition,
innate inflammatory responses are also modulated by apoE
and LRP1, implying that apoE may have general anti-inflamma-
tory effects (LaDu et al., 2000b). It is tempting to speculate that
the interaction and subsequent codeposition of Ab with apoE
might serve to compromise the anti-inflammatory function of
apoE by reducing the functionally available pool size of apoE,
eventually leading to chronic neuroinflammation. Consistent
with the anti-inflammatory role of apoE in vitro, lack of apoE
expression in mice was associated with increased inflammation,
including induction of several cytokines and proinflammatory
responses, in response to treatment of Ab and other activating
stimuli (LaDu et al., 2001; Lynch et al., 2001). Glial activation
and subsequent apoE induction appear to be mediated, at least
in part, by the nuclear factor-kb (NF-kb) transcription factor
(Bales et al., 2000).
ApoE Isoforms and Neuroinflammation
If there are apoE isoform-dependent differences in the anti-
inflammatory function of apoE in vivo, such differences might
in part explain the differential risk for AD caused by apoE
isoforms. In support of this hypothesis, several studies demon-
strated that exogenously applied apoE4 has more robust proin-
flammatory activity than apoE3 in astrocytes and microglial cells
(Barger and Harmon, 1997; Guo et al., 2004). In addition, apoE
isoform-specific effects on neuroinflammation have been
studied in vivo with human apoE knockin mice. After intravenous
administration of LPS, apoE4 knockin mice had greater inflam-
matory responses compared with apoE3 knockin mice (Colton
et al., 2004; Lynch et al., 2003). Taken together, these data
suggest that apoE4 may have proinflammatory or less effective
anti-inflammatory function and therefore may exacerbate or
inefficiently prevent the detrimental neuroinflammation in AD,compared with the apoE3 isoform. However, it is still not known
whether apoE2 modulates any inflammatory process triggered
by Ab. Although it is interesting to note that apoE is involved in
the presentation of exogenous lipid antigens (van den Elzen
et al., 2005), how apoE exerts its effects on immune responses
still remains unclear. The role of apoE in the inflammation asso-
ciated with AD pathogenesis needs to be further investigated
with genetic and pharmacological manipulations of specific
inflammatory pathways.
The Effect of ApoE on Metabolic Alterations in the Brain
Despite the steady effort to link apoE with the specific disease
pathogenesis of AD within the brain, the possibility remains
that apoE indirectly affects AD onset and progression by modu-
lating the function of the cerebrovascular system. The apoE4
isoform has been linked with increased levels of LDL and has
been demonstrated to be a risk factor for cardiovascular disease
(Song et al., 2004; Wilson et al., 1994). As a result, increased
levels of atherosclerosis associated with apoE4 (Elosua et al.,
2004; Graner et al., 2008) could have detrimental effects on brain
function through decreased blood flow and altered metabolic
properties. Positron emission tomography (PET) studies have
shown that AD brains exhibit decreased glucose metabolism in
distinct regions (Alexander et al., 2002; Minoshima et al.,
1995). Furthermore, studies looking at both young and old non-
demented carriers of the apoE4 isoform observed a similar
regional pattern of hypometabolism prior to the onset of disease
that correlates with the changes seen in the AD brain. This
suggests the possibility that an apoE-related decrease in brain
metabolism may contribute to development of AD (Reiman
et al., 1996; Reiman et al., 2004, 2005; Small et al., 2000).
Whether these observations in apoE4 individuals are due to
a direct effect of apoE4 on brain metabolism or simply an indirect
effect of the early stages of apoE4-induced early amyloid forma-
tion with resulting decreased synaptic activity and brain metab-
olism remains to be determined. Therefore, further studies will be
important to clarify the role of apoE4-related decreased brain
metabolism and whether the presence of apoE4 directly
promotes the metabolic changes that occur during the disease
process or it indirectly affects brain metabolism via effects on
amyloid or possibly effects on the cerebrovasculature.
Concluding Remarks
Prevailing data suggest that the main effect of apoE isoforms on
risk for AD is via the effect of apoE on Abmetabolism, influencing
the time of onset of Ab deposition in both brain parenchyma and
vasculature (Figure 1). By influencing the onset, location, and
amount of Ab aggregation in the brain, this is then likely to trigger
a set of downstream events that ultimately culminates in AD,
CAA, or both. Since apoE modulates not only clearance but
also aggregation of Ab as well as other neuropathological
changes, it has been difficult to elucidate the exact pathological
mechanism behind the observed Ab phenotypes in human and
animal studies. A critical but still unresolved question is whether
theAPOE 34 allele influences AD pathogenesis, by a gain of toxic
function, a loss of protective function, or a combination of both. A
similar issue regarding the role of PSEN mutations in AD has
been debated recently (Bentahir et al., 2006; Shen and Kelleher,Neuron 63, August 13, 2009 ª2009 Elsevier Inc. 295
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mechanisms of apoE4 in AD, two different therapeutic strategies
are currently being considered; one trying to decrease the
toxic effects of apoE4 by altering its structure and the other at-
tempting to restore the physiological functions of apoE/apoE4
by increasing its expression and function. In addition, influencing
the lipidation of apoE as well as targeting apoE receptors such as
LDLR and LRP is also a potential strategy for future therapeutic
design. Further studies are warranted to tease out how much
Ab versus non-Ab-mediated effects of apoE influence AD.
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